CA
LENZ

Cliff Asness’s LENZ Therapeutics LENZ Stock Holding History

Cliff Asness’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Buy
227,732
+87,427
+62% +$705K ﹤0.01% 2866
2026
Q1 		$1.28M Buy
+140,305
New +$1.97M ﹤0.01% 2636

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Cliff Asness's LENZ Position: Q2 2026 in Review

Cliff Asness increased its LENZ Therapeutics (LENZ) stake by 62% in Q2 2026, buying an estimated $705K and bringing the position to 227,732 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2866.

Cliff Asness first reported a position in LENZ in Q1 2026 and has held it in 2 quarters since. 143 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Cliff Asness held 227,732 shares of LENZ Therapeutics worth $1.29M as of Q2 2026.
  • Cliff Asness bought 87,427 LENZ Therapeutics shares in Q2 2026, an estimated $705K.
  • LENZ Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2866 holding.
  • Cliff Asness first reported a position in LENZ Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 143 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.